Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are adjusted ...

Nevro Corp (NYSE:NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Nevro (NVRO) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

What Are the BATMMAAN Stocks? If you're ready to move beyond Magnificent Seven stocks, there's a new acronym on Wall Street with one key addition.